MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on March 18, 2005; DOI: 10.1124/mol.104.008169


0026-895X/05/6706-2088-2101$20.00
Mol Pharmacol 67:2088-2101, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.008169v1
67/6/2088    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Martínez-Jiménez, C. P.
Right arrow Articles by Jover, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martínez-Jiménez, C. P.
Right arrow Articles by Jover, R.

Transcriptional Regulation of the Human Hepatic CYP3A4: Identification of a New Distal Enhancer Region Responsive to CCAAT/Enhancer-Binding Protein {beta} Isoforms (Liver Activating Protein and Liver Inhibitory Protein)

Celia P. Martínez-Jiménez, M. José Gómez-Lechón, José V. Castell, and Ramiro Jover

Unidad de Hepatología Experimental, Centro de Investigación, Hospital Universitario "La Fe", Valencia, Spain (C.P.M.-J., M.J.G.-L., J.V.C., R.J.); and Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Valencia, Spain (C.P.M.-J., J.V.C., R.J.)

CCAAT/enhancer-binding proteins (C/EBPs) are key transcription factors involved in the constitutive expression of several cytochrome P450 genes in the liver. Their concentration and activity change in several pathophysiological conditions. For instance, during inflammation, released cytokines induce repressive C/EBP{beta}-liver inhibitory protein (LIP), which antagonizes constitutive C/EBP transactivators [C/EBP{alpha} and C/EBP{beta}-liver activating protein (LAP)], down-regulating genes such as CYP3A4. However, the mechanism by which hepatic C/EBP factors modulate transcription of the CYP3A4 gene is not known. To elucidate the mechanism of action, we cotransfected luciferase reporter vectors, containing 5'-flanking deletions of the CYP3A4 gene, along with expression vectors for C/EBP{beta}-LAP, C/EBP{beta}-LIP, and C/EBP{alpha}, in hepatic (HepG2) and nonhepatic (HeLa) cells. Analysis of the –3557 to –6954 base pair (bp) region demonstrated the existence of a 288-bp sequence at –5.95 kilobases (kb), which showed maximal response to C/EBP{beta}-LAP (~30-fold increase in HepG2 cells). Coexpression of LAP with increasing amounts of LIP reduced the activating effect by ~70%. Site-directed mutagenesis of predicted C/EBP{beta} binding sites demonstrated the presence of four functional C/EBP{beta}-responsive motifs within this distal flanking region. Further experiments using chromatin immunoprecipitation proved the binding of endogenous C/EBP{beta} to the –5.95-kilobase enhancer of the CYP3A4 gene in human hepatocytes. Expression of recombinant LAP and LIP by means of adenoviral vectors resulted in their binding to this region, which was followed by activation/repression of CYP3A4. Together, our results uncover a new distal enhancer site in the CYP3A4 gene where C/EBP{beta}-LAP binds and activates transcription, whereas the truncated form, C/EBP{beta}-LIP, antagonizes LAP activity and causes gene repression.


Received for publication October 19, 2004.

Accepted for publication March 18, 2005.

Address correspondence to: Dr. Ramiro Jover Atienza, Unidad de Hepatología Experimental, Centro de Investigación, Hospital La Fe, Avenida de Campanar, 21, 46009 Valencia, Spain. E-mail: ramiro.jover{at}uv.es




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
X. Qiu, K. J. Aiken, A. L. Chokas, D. E. Beachy, and H. S. Nick
Distinct Functions of CCAAT Enhancer-binding Protein Isoforms in the Regulation of Manganese Superoxide Dismutase during Interleukin-1{beta} Stimulation
J. Biol. Chem., September 19, 2008; 283(38): 25774 - 25785.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
M. A. Kramer, A. E. Rettie, M. J. Rieder, E. T. Cabacungan, and R. N. Hines
Novel CYP2C9 Promoter Variants and Assessment of Their Impact on Gene Expression
Mol. Pharmacol., June 1, 2008; 73(6): 1751 - 1760.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
A. E. Aitken and E. T. Morgan
Gene-Specific Effects of Inflammatory Cytokines on Cytochrome P450 2C, 2B6 and 3A4 mRNA Levels in Human Hepatocytes
Drug Metab. Dispos., September 1, 2007; 35(9): 1687 - 1693.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. Ling, Y. Wei, and X. Ding
Transcriptional Regulation of Human CYP2A13 Expression in the Respiratory Tract by CCAAT/Enhancer Binding Protein and Epigenetic Modulation
Mol. Pharmacol., March 1, 2007; 71(3): 807 - 816.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. P. Martinez-Jimenez, J. V. Castell, M. J. Gomez-Lechon, and R. Jover
Transcriptional Activation of CYP2C9, CYP1A1, and CYP1A2 by Hepatocyte Nuclear Factor 4{alpha} Requires Coactivators Peroxisomal Proliferator Activated Receptor-{gamma} Coactivator 1{alpha} and Steroid Receptor Coactivator 1
Mol. Pharmacol., November 1, 2006; 70(5): 1681 - 1692.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
X. Gu, S. Ke, D. Liu, T. Sheng, P. E. Thomas, A. B. Rabson, M. A. Gallo, W. Xie, and Y. Tian
Role of NF-{kappa}B in Regulation of PXR-mediated Gene Expression: A MECHANISM FOR THE SUPPRESSION OF CYTOCHROME P-450 3A4 BY PROINFLAMMATORY AGENTS
J. Biol. Chem., June 30, 2006; 281(26): 17882 - 17889.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics